Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter

  • Javier E. BanchsEmail author
  • Deborah L. Wolbrette
  • Soraya M. Samii
  • Erica D. Penny-Peterson
  • Parag P. Patel
  • Sallie K. Young
  • Mario D. Gonzalez
  • Gerald V. Naccarelli



Dofetilide, an IKr blocker has been demonstrated to be effective in terminating persistent atrial fibrillation and flutter (AF/AFL), and in maintaining sinus rhythm after direct current cardioversion (CV). It is not known, however, whether pharmacological conversion with dofetilide predicts maintenance of sinus rhythm. In addition, there is limited information comparing the efficacy of dofetilide in persistent versus paroxysmal AF/AFL.

Methods and Results

Eighty consecutive patients with AF/AFL (51 persistent, 29 paroxysmal) admitted for initiation of dofetilide were studied. Termination of persistent AF/AFL occurred in 61% of patients while 39% required CV. After 21 ± 19 months of follow-up, 37% of patients with persistent AF/AFL were free of recurrence. Acute conversion with dofetilide did not predict long term efficacy. Dofetilide was more effective in maintaining sinus rhythm in patients with AFL (65%) than in those with AF (25%) (p < 0.05). Dofetilide was more likely to maintain sinus rhythm in patients with persistent than paroxysmal AF/AFL (37 vs. 14%; p < 0.05). Torsades de Pointes developed in two patients despite careful dosing and monitoring of QT changes.


Dofetilide is more effective in patients with persistent than in those with paroxysmal AF/AFL. Importantly, short-term response does not necessarily predict long-term efficacy. Significant proarrhythmia can occur even with careful in-hospital monitoring.


Atrial fibrillation Dofetilide Antiarrhythmic drugs 


  1. 1.
    Fuster, V., Ryden, L. E., Cannom, D. S., et al. (2006). ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation, 114, e257–e354.PubMedCrossRefGoogle Scholar
  2. 2.
    Gwilt, M., Arrowsmith, J. E., Blackburn, K. J., et al. (1991). UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. The Journal of Pharmacology and Experimental Therapeutics, 256, 318–324.PubMedGoogle Scholar
  3. 3.
    Mounsey, J. P., & DiMarco, J. P. (2000). Cardiovascular drugs. Dofetilide. Circulation, 102, 2665–2670.PubMedGoogle Scholar
  4. 4.
    Roukoz, H., & Saliba, W. (2007). Dofetilide: a new class III antiarrhythmic agent. Expert Review of Cardiovascular Therapy, 5(1), 9–19.PubMedCrossRefGoogle Scholar
  5. 5.
    Greenbaum, R. A. (1999). Meeting highlights: highlights of the 71st Scientific Sessions of the American Heart Association. The EMERALD trial. Circulation, 99, 2486–2491.Google Scholar
  6. 6.
    Singh, S., Zoble, R. G., Yellen, L., et al. (2000). Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on defetilide (SAFIRE-D) study. Circulation, 102, 2385–2390.PubMedGoogle Scholar
  7. 7.
    Torp-Pedersen, C., Moller, M., Bloch-Thomsen, P. E., et al. (1999). Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. The New England Journal of Medicine, 341, 857–865.PubMedCrossRefGoogle Scholar
  8. 8.
    Kober, L., Bloch Thompsen, P. E., Moller, M., et al. (2000). Effect of dofetilide in patients with recent myocardial infarction and left ventricular dysfunction: a randomized trial. Lancet, 356, 2052–2058.PubMedCrossRefGoogle Scholar
  9. 9.
    Pedersen, O. D., Bagger, H., Keller, N., & Marchant, B. (2001). kober l, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation–flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation, 104, 292–296.PubMedGoogle Scholar
  10. 10.
    Prystowsky, E. N., Freeland, S., Branyas, N. A., et al. (2003). Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 14, S287–S290.PubMedCrossRefGoogle Scholar
  11. 11.
    Mykytsey, A., Bauman, J. L., Razminia, M., et al. (2007). Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. Journal of Cardiovascular Pharmacology and Therapeutics, 12, 36–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Cotiga, D., Arshad, A., Aziz, E., et al. (2007). Acute conversion of persistent atrial fibrillation during dofetilide initiation. Pacing and Clinical Electrophysiology, 30, 1527–1530.PubMedGoogle Scholar
  13. 13.
    Feld, G. K., & Cha, Y. (1997). Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide in an experimental canine model of pacing-induced atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2(3), 195–203.PubMedCrossRefGoogle Scholar
  14. 14.
    Tai, C. T., & Chen, S. A. (2001). Mechanisms of antiarrhythmic drug action on termination of atrial flutter. Pacing and Clinical Electrophysiology, 24, 824–834.PubMedCrossRefGoogle Scholar
  15. 15.
    Falk, R. H., Pollak, A., Singh, S. N., et al. (1997). Intravenous dofetilide a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. Journal of the American College of Cardiology, 29(2), 385–390.PubMedCrossRefGoogle Scholar
  16. 16.
    Stambler, B. S., Wood, M. A., & Ellenbogen, K. A. (1997). Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Electrophysiological determinants of enhanced conversion efficacy. Circulation, 96, 4298–4306.PubMedGoogle Scholar
  17. 17.
    Wirth, K. J., & Knobloch, K. (2001). Differential effects of dofetilide, amiodarone, and class Ic drugs on left and right atrial refractoriness and left atrial vulnerability in pigs. Naunyn-Schmiedeberg’s Archives of Pharmacology, 363, 166–174.PubMedCrossRefGoogle Scholar
  18. 18.
    Knobloch, K., Brendel, J., Peukert, S., et al. (2002). Electrophysiological and antiarrhythmic effects of the novel Ikur channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn-Schmiedeberg’s Archives of Pharmacology, 366, 482–487.PubMedCrossRefGoogle Scholar
  19. 19.
    Waldo, A. L. (2002). Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin. Cardiovascular Research, 54, 216–229.CrossRefGoogle Scholar
  20. 20.
    Waldo, A. L., & Feld, G. K. (2008). Inter-relationships of atrial fibrillation and atrial flutter. Journal of the American College of Cardiology, 51, 779–786.PubMedCrossRefGoogle Scholar
  21. 21.
    Cappato, R., Calkins, H., Chen, S. A., et al. (2005). Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation, 111, 1100–1105.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Javier E. Banchs
    • 1
    Email author
  • Deborah L. Wolbrette
    • 1
  • Soraya M. Samii
    • 1
  • Erica D. Penny-Peterson
    • 1
  • Parag P. Patel
    • 1
  • Sallie K. Young
    • 2
  • Mario D. Gonzalez
    • 1
  • Gerald V. Naccarelli
    • 1
  1. 1.Penn State Heart and Vascular Institute, Milton S. Hershey Medical CenterPenn State UniversityHersheyUSA
  2. 2.Department of PharmacyPenn State UniversityHersheyUSA

Personalised recommendations